SAFETY, IMMUNOGENICITY AND IMPACT ON PARASITE MULTIPLICATION RATES OF THE CANDIDATE BLOOD-STAGE VACCINE AMA1-C1/ALHYDROGEL WITH THE NOVEL ADJUVANT CPG 7909 AGAINST BLOOD-STAGE MALARIA CHALLENGE IN HEALTHY MALARIA-NAIVE VOLUNTEERS
Main Authors: | Duncan, C, Sheehy, S, Ewer, K, Douglas, A, Halstead, F, Edwards, N, Collins, K, Lillie, P, Poulton, I, Hunt-Cooke, A, Lawrie, A, Draper, S, Gilbert, S, Fay, M, Miura, K, Long, C, Wu, Y, Hill, A, Ellis, R |
---|---|
Formato: | Conference item |
Publicado: |
2010
|
Títulos similares
-
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.
por: Duncan, C, et al.
Publicado: (2011) -
Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
por: Ruth D Ellis, et al.
Publicado: (2012-01-01) -
Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
por: Ruth D Ellis, et al.
Publicado: (2010-01-01) -
Viral vectored blood-stage malaria vaccines induce B cell responses in humans that can be boosted by controlled malaria infection
por: Elias, S, et al.
Publicado: (2014) -
Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
por: Elias, S, et al.
Publicado: (2013)